The Romanian Acute Heart Failure Syndromes (RO-AHFS) Registry

Chioncel, Ovidiu; Vinereanu, Dragoş; Datcu, Mihai Dan; Ionescu, Dan; Căpâlneanu, R.; Brukner, Ioan; Dorobanțu, Maria; Ambrosy, Andrew P.; Macarie, Cezar; Gheorghiade, Mihai

doi:10.1016/j.ahj.2011.03.033

Cited by 56 publications

(49 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Level 1 factors showed increased mortality in older 16,26,[49][50][51][52][53] patients, while the results for gender were mixed, with three studies showing no difference, 16,54,55 three showing increased mortality, 9,51,56 and one decreased 52 mortality. Black HF patients had decreased mortality.…”

Section: Social Factors Associated With Mortality In Heart Failurementioning

confidence: 99%

Impact of Social Factors on Risk of Readmission or Mortality in Pneumonia and Heart Failure: Systematic Review

et al. 2012

View full text Add to dashboard Cite

Section: Social Factors Associated With Mortality In Heart Failurementioning

confidence: 99%

Impact of Social Factors on Risk of Readmission or Mortality in Pneumonia and Heart Failure: Systematic Review

et al. 2012

View full text Add to dashboard Cite

“…For the latter endpoint, we considered only AHF patients hospitalized after ED presentation (patients directly discharged from the ED without hospitalization were excluded) who were discharged home alive (patients dying during hospitalization were excluded). Since data from previous studies have shown that the mean length of hospitalization in patients with AHF ranges between 6 and 10 days [6,[26][27][28], we defined prolonged hospitalization as that exceeding 10 days.…”

Section: Methodsmentioning

confidence: 99%

BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure

Miró¹,

Müller

Martín‐Sánchez

et al. 2016

Clin Res Cardiol

View full text Add to dashboard Cite

show abstract

“…13,25 Our understanding of varying global profiles of HHF is predominantly from large multicenter registries in Europe, the United States, parts of the Middle East, and some Asian Pacific nations (Table II). 8,17,26,27–39 Until recently, HHF registry data from South and Central America came largely from a few Argentinean registries. 40 Emerging data from ADHERE-international is adding essential information from Mexico and Brazil.…”

Section: Challenges In Hhf Trialsmentioning

confidence: 99%

Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries

Greene

Shah

Butler

et al. 2014

American Heart Journal

Self Cite

View full text Add to dashboard Cite

Recent international phase III clinical trials of novel therapies for hospitalized heart failure (HHF) have failed to improve the unacceptably high postdischarge event rate. These large studies have demonstrated notable geographic and site-specific variation in patient profiles and enrollment. Possible contributors to the lack of success in HHF outcome trials include challenges in selecting clinical sites capable of (1) providing adequate numbers of appropriately selected patients and (2) properly executing the study protocol. We propose a “pretrial registry” as a novel tool for improving the efficiency and quality of international HHF trials by focusing on the selection and cultivation of high-quality sites. A pretrial registry may help assess a site’s ability to achieve adequate enrollment of the target patient population, integrate protocol requirements into clinical workflow, and accomplish appropriate follow-up. Although such a process would be associated with additional upfront resource investment, this appropriation may be modest in comparison with the downstream costs associated with maintenance of poorly performing sites, failed clinical trials, and the global health and economic burden of HHF. This review is based on discussions between scientists, clinical trialists, and regulatory representatives regarding methods for improving international HHF trials that took place at the United States Food and Drug Administration on January 12th, 2012.

show abstract

The Romanian Acute Heart Failure Syndromes (RO-AHFS) Registry

Cited by 56 publications

References 29 publications

Impact of Social Factors on Risk of Readmission or Mortality in Pneumonia and Heart Failure: Systematic Review

Impact of Social Factors on Risk of Readmission or Mortality in Pneumonia and Heart Failure: Systematic Review

BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure

Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries

Contact Info

Product

Resources

About